Bayer Names Pfizer’s Brandicourt Healthcare Division CEO
This article was originally published in The Pink Sheet Daily
The broadly experienced pharmaceutical executive – who has specialized particularly in emerging markets and infectious diseases – inherits a healthcare division that is in the midst of several product launches and has few near-term patent expirees.
You may also be interested in...
Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.
David Simmons, head of established products and emerging markets at Pfizer, has jumped ship to lead global CRO PPD Inc. Olivier Brandicourt, currently head of primary care at the big pharma, will take Simmons’ place.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.